Literature DB >> 10806853

Variations and clinical significance of coagulation and fibrinolysis parameters in patients with diabetes mellitus.

J Hu1, W Wei, G Din, L Yuan, Z Liu.   

Abstract

We observed the changes of parameters of coagulation and fibrinolytic system in order to understand the clinical implication of these variations in type II diabetic patients. Subjects consisted of 22 patients with type II diabetes mellitus and 25 healthy controls. Compared with the control, activated partial thromboplastin time, prothrombin time were shortened in the patients. The diabetic subjects also displayed higher levels of D-dimer, serum fibrin degradation products, median concentrations of fibrinogen (3.99 vs 2.96 g/L, P < 0.01) and von Willebrand factor (149% vs 87%, P < 0.01). Levels of antithrombin III activity or antigen were not different from control values. Simple linear regression analysis revealed a negative correlation between antithrombin III activity and fast blood glucose. Diabetic patients with vascular complications had significantly higher levels of fibrinogen and D-dimer than those without diabetic angiopathy. Our data demonstrated that patients with type II diabetes mellitus had a hypercoagulable state. We believed the activation of coagulation might contribute to the vascular complications in diabetics.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10806853     DOI: 10.1007/bf02886480

Source DB:  PubMed          Journal:  J Tongji Med Univ        ISSN: 0257-716X


  9 in total

Review 1.  Markers of activated coagulation and their usefulness in the clinical laboratory.

Authors:  A Tripodi; P M Mannucci
Journal:  Clin Chem       Date:  1996-05       Impact factor: 8.327

2.  Measurement of plasma fibrin D-dimer levels with the use of a monoclonal antibody coupled to latex beads.

Authors:  C S Greenberg; D V Devine; K M McCrae
Journal:  Am J Clin Pathol       Date:  1987-01       Impact factor: 2.493

Review 3.  Vascular thrombosis in type II diabetes mellitus.

Authors:  J A Colwell
Journal:  Diabetes       Date:  1993-01       Impact factor: 9.461

4.  Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study.

Authors:  A J Lee; G D Lowe; M Woodward; H Tunstall-Pedoe
Journal:  Br Heart J       Date:  1993-04

5.  Fibrinogen plasma levels as a marker of thrombin activation: new insights on the role of fibrinogen as a cardiovascular risk factor.

Authors:  A Ceriello; M Pirisi; R Giacomello; G Stel; E Falleti; E Motz; S Lizzio; F Gonano; E Bartoli
Journal:  Thromb Haemost       Date:  1994-05       Impact factor: 5.249

6.  Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients.

Authors:  P Knöbl; G Schernthaner; C Schnack; P Pietschmann; S Proidl; R Prager; T Vukovich
Journal:  Thromb Haemost       Date:  1994-06       Impact factor: 5.249

7.  The PLAT Study: a multidisciplinary study of hemostatic function and conventional risk factors in vascular disease patients.

Authors:  M Cortellaro; C Boschetti; E Cofrancesco; C Zanussi; M Catalano; G de Gaetano; L Gabrielli; B Lombardi; G Specchia; L Tavazzi
Journal:  Atherosclerosis       Date:  1991-10       Impact factor: 5.162

8.  Fibrinogen plasma levels as a marker of thrombin activation in diabetes.

Authors:  A Ceriello; C Taboga; R Giacomello; E Falleti; G De Stasio; E Motz; S Lizzio; F Gonano; E Bartoli
Journal:  Diabetes       Date:  1994-03       Impact factor: 9.461

9.  Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus.

Authors:  F Carmassi; M Morale; R Puccetti; F De Negri; F Monzani; R Navalesi; G Mariani
Journal:  Thromb Res       Date:  1992-09-15       Impact factor: 3.944

  9 in total
  1 in total

Review 1.  Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS.

Authors:  H J Teede; S Hutchison; S Zoungas; C Meyer
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.